SR One related stories
All articles and analysis
Aileron Therapeutics grabs $33 mln Series EAileron Therapeutics has raised $33 million in Series E funding. The investors included AJU IB Investment Co., Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis Venture Funds, Roche Venture Fund and SR One. Based in Cambridge, Mass., Aileron Therapeutics is a clinical stage biopharmaceutical firm that is developing therapeutics based on its proprietary Stapled Peptide drug platform.
- Bicycle Therapeutics reels in $32 mln
Bicycle Therapeutics has raised $32 million in funding. Previous backers Atlas Venture, Novartis Venture Fund, SR One, SV Life Sciences and Astellas Venture Management all participated in the round. Based in Cambridge, UK, Bicycle Therapeutics is a biotech firm focused on developing bicyclic peptides.
- Atopix picks up funding from SR One
Atopix has received an undisclosed investment from SR One, the corporate venture capital arm of GlaxoSmithKline. Also, the company has added Dr. Deborah Harland, a partner at SR One, to its board of directors. Based in the UK, Atopix is a biopharmaceutical company focused on treating allergic disease.
J&J to acquire VC-backed Alios BioPharma for $1.75 blnJohnson & Johnson has agreed to buy Alios BioPharma for about $1.75 billion in cash.
Fonds de solidarité FTQ's Gravel, Orbimed's Zakrzewski join Thrasos boardThrasos Therapeutics, a biotherapeutics company focused on delivering new treatments for kidney disease, has appointed Gaétan Gravel and Joe Zakrzewski to its board of directors. Gravel is the life sciences portfolio director at the Fonds de solidarité des travailleurs du Québec FTQ. Zakrzewski was between 2010 and 2011 a venture partner at U.S. venture capital firm Orbimed Advisors. In 2012, Montréal's Thrasos raised $35 million from SR One, GSK Canada Life Sciences Innovation Fund, SW Co, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.
- Atox Bio raises $23 mln to fund flesh-eating bacteria treatment: Reuters
Israel-based Atox Bio, a developer of therapeutics for severe infections, said on Thursday it has raised $23 million in an investment round led by SR One, the healthcare venture capital fund of GlaxoSmithKline.
Venture-backed Thrasos Therapeutics hires new SVP and CFOThrasos Therapeutics Inc has hired Donald Notman as senior vice president and CFO. Previously, Notman worked at Leerink Partners as managing director and head of private capital markets. Based in Montréal, Thrasos is a biotherapeutics company focused on delivering new solutions for treating kidney disease. Update: In 2012, the company raised $35 million in a round led by SR One and with the participation of GSK Canada Life Sciences Innovation Fund, SW Co, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.
- Venture-backed Thrasos Therapeutics hires new SVP and CFO
Thrasos Therapeutics Inc has hired Donald Notman as senior vice president and CFO. Previously, Notman worked at Leerink Partners as managing director and head of private capital markets. Based in Montréal, Thrasos is a biotherapeutics company focused on delivering new solutions for treating kidney disease. Update: In 2012, the company raised $35 million in a round led by SR One and with the participation of GSK Canada Life Sciences Innovation Fund, SW Co, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.
- Navitor Pharmaceuticals closes $23.5 mln Series A
Biopharmaceutical company Navitor Pharmaceuticals has closed a $23.5 million Series A financing. Investors include Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund. Inc.
- True North Therapeutics bags $22 mln Series A
South San Francisco-based biotech firm True North Therapeutics has closed $22 million in Series A funding. The investors included Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures and Baxter Ventures.